Resources Repository
-
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Health Outcomes | Europe | Preferences/Values | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Health Systems | Health/Medicine | Science/Technology | North America -
ArticlePublication 2016Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?
Timely implementation of recommended interventions can provide health benefits to patients and cost savings to …
Timely implementation of recommended interventions can provide health benefits to patients and cost savings to the health service provider. Effective approaches to increase the implementation of guidance are needed. Since investment in activities that improve implementation competes for funding against other health generating interventions, it should be assessed in term of its costs and benefits. In 2010, the National Institute for Health and Care Excellence released a clinical guideline recommending natriuretic peptide (NP) testing in…
Health Outcomes | Europe | Cost-Effectiveness Analysis | Operations Research | Chronic Disease/Risk | Health Systems | Clinical Care | Economics/Finance | Health/Medicine -
ArticlePublication 2017Predicting Carer Health Effects for Use in Economic Evaluation
Illnesses and interventions can affect the health status of family carers in addition to patients. …
Illnesses and interventions can affect the health status of family carers in addition to patients. However economic evaluation studies rarely incorporate data on health status of carers. In order to investigate whether changes in carer health status could be ‘predicted’ from the health data of those they provide care to, as a means of incorporating carer outcomes in economic evaluation, the authors used regression models to analyse changes in carers’ health status. They derive predictive algorithms based on…
Health Outcomes | Europe | Preferences/Values | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine | North America -
GuidelinesPublication 2013Guide to the Methods of Technology Appraisal 2013
The National Institute for Health and Care Excellence (NICE, or the Institute) provides guidance to …
The National Institute for Health and Care Excellence (NICE, or the Institute) provides guidance to the NHS in England on the clinical and cost effectiveness of selected new and established technologies. The Institute undertakes appraisals of health technologies at the request of the Department of Health. Guidance produced by the Institute on health technologies is also applied selectively in Northern Ireland, Scotland and Wales. The purpose of this document is to provide an overview of…
Europe | Priority Setting/Ethics | Cost-Effectiveness Analysis | Technology Assessment | Health Systems | Policy/Regulation | Government/Law | Health/Medicine -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Europe | Value of Information | State-Transition | Benefit-Cost Analysis | Infectious Diseases | Policy/Regulation | Economics/Finance | North America -
ArticlePublication 2018DALYS and QALYs – Does the Choice of Measure Matter?
This article discusses the measurement of health benefits as a key issue in health economic …
This article discusses the measurement of health benefits as a key issue in health economic evaluations. Authors adapted two previously published models, a Markov model for human papilloma virus (HPV) vaccination, and a pneumococcal vaccination deterministic model (PNEUMO) that reported outputs in QALYs to estimate DALYs in 3 settings, Argentina, Chile, and the United Kingdom. While the authors found that QALY gains were larger than DALYs avoided in all countries for HPV, differences using QALYs…
Europe | Cost-Effectiveness Analysis | Infectious Diseases | Policy/Regulation | Health/Medicine | Latin America & Caribbean -
ArticlePublication 2016Country-Level Cost-Effectiveness Thresholds
This article estimates the cost-effectiveness thresholds (CETs) for health interventions in several low and middle-income …
This article estimates the cost-effectiveness thresholds (CETs) for health interventions in several low and middle-income countries (LMICs), based on opportunity costs. When there are constraints on a health care system’s budget or ability to increase expenditures, additional costs imposed by interventions have an “opportunity cost” in terms of the health foregone because other interventions cannot be provided. The authors argue that cost-effectiveness thresholds should reflect health opportunity cost and aim to calculate these in four…
Europe | Priority Setting/Ethics | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2016Cost-Effectiveness of Collaborative Care for Depression and Comorbid Diabetes or CVD
This article, published in BMJ Open, presents an economic model that combines a decision tree …
This article, published in BMJ Open, presents an economic model that combines a decision tree and a Markov cohort model to investigate the long-term cost-effectiveness of collaborative care versus usual care for individuals with depression and comorbid diabetes and/or cardiovascular disease. Data from the COINCIDE trial informs the model input parameters. The COINCIDE trial is a randomized controlled trial of collaborative care versus usual care that enrolled 387 participants from 36 primary care general practices…
Europe | State-Transition | Cost-Effectiveness Analysis | Chronic Disease/Risk | Mental Health | Health/Medicine -
GuidelinesPublication 2016Methods for Health Economic Evaluation of Vaccines
This article describes the development of a consensus for health economic evaluations of vaccines to …
This article describes the development of a consensus for health economic evaluations of vaccines to support the development of national guidelines in Europe. While guidelines advocating more standardization of health economic evaluations exist, this article aims to address several immunization-specific aspects (e.g. indirect effects or discounting approach) which are still a subject of debate. The systematic literature review search was informed by expert opinion. 2,838 articles were returned from the search and 26 were finally…
Europe | Costing Methods | Dynamic Transmission | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Health/Medicine